Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Founder operating in the Therapeutics space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Chris Gibson
Co-Founder & CEO of Recursion Pharmaceuticals
Chris completed his PhD in Bioengineering at the University of Utah in the fall of 2013 before taking a leave of absence from medical school (he was enrolled in the MD/PhD program) to found and grow Recursion. He developed the core technology underlying this venture while in the lab of Dr. Dean Li. Chris comes from a family of entrepreneurs, is a graduate of Rice University with degrees in bioengineering and managerial studies, and recently completed an intense course in entrepreneurship at Stanford GSB. Chris is also a Board Member of CureHHT, a patient advocacy group for Hereditary Hemorrhagic Telangiectasia. Chris enjoys cycling on both the road and the trails that cut through Utah’s great wilderness,as well as spending precious time with his family.
Follow Chris Gibson:
About Recursion Pharmaceuticals: Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Stephanie Tilenius
CEO, Founder of Vida Health
Stephanie is CEO & Founder of Vida Health.
Follow Stephanie Tilenius:
About Nextdoor, Vida Health: Vida Health is a virtual care platform that provides health coaching from experienced health care providers and medical institutions.
Erica Johnson
Co-Founder of Modern Health
Follow Erica Johnson:
About Modern Health: Modern Health is a mental well-being platform for innovative companies offering therapy, coaching, and self-guided courses all in one app.
Alyson Watson
Founder & CEO of Modern Health
Alyson Friedensohn is a founder and CEO at Modern Health.
Follow Alyson Watson:
About Modern Health: Modern Health is a mental well-being platform for innovative companies offering therapy, coaching, and self-guided courses all in one app.
Raja Dhir
Co-Founder and Co-CEO of Seed Health
Raja Dhir is a life sciences entrepreneur and Co-Founder of Seed Health, a venture-backed microbiome company pioneering the application of bacteria for both human and planetary health. He leads Seed’s R&D, academic collaborations, technology development, clinical trial design, supply chain, and intellectual property strategy. Together with Dr. Jacques Ravel, he Co-Chairs Seed’s Scientific Advisory Board–an interdisciplinary group of scientists and doctors who lead research teams and teach at institutions including the teaching hospital of Harvard Medical School and the Trial Innovation Unit of Mass. General Hospital (MGH). Raja has designed clinical trials with leading academic institutions including the teaching hospital of Harvard Medical School and the Trial Innovation Unit of Mass. General Hospital (MGH). Raja has unique expertise translating scientific research for product development with a track record that includes patented inventions to stabilize sensitive compounds to improve alpha-diversity of the gut microbiome (derived from micro-algae) and most recently, the co-invention of microbial technologies to protect honeybee populations (Apis mellifera) from neonicotinoid pesticides and pathogen colonization. His work also includes biofermentation and scale-up for both facultative and strict anaerobic organisms. Raja has negotiated multiple joint-ventures, strategic partnerships, technology transfer and licensing agreements with publicly traded companies (NYSE, LSE) and academic institutions (Harvard Medical School, UCLA). To date, entities he has co-founded own the rights to 15+ patents and research emerging from $25MM+ of non-dilutive funding over 10+ years from the Bill and Melinda Gates Foundation and National Institute of Health (NIH). Raja serves on the Editorial Board for the scientific journal, Microbiome. He is a member of the Microbiome Think Tank at Mass. General Hospital (MGH) and sits on the Advisory Committee for the International Scientific Association of Probiotics and Prebiotics (ISAPP). Raja is also a Director and Co-Chair of the Scientific Advisory Board for Micropia, a $20MM microbial ecology / education platform and the world’s first museum dedicated to microbes.
Follow Raja Dhir:
About Seed Health: Seed Health is a microbial company that focuses on therapeutics, consumer health innovations, and environmental solutions.
Ara Katz
Co-Founder and Co-CEO of Seed Health
Ara Katz is the Co-Founder and Co-CEO of Seed Health, a microbial sciences company pioneering the application of bacteria to impact human and planetary health. She has worked at the intersection of technology, consumer, design, and media is now working to steward a new standard in probiotics and how science is communicated to change how we discern evidence from evangelism to make the most informed choices for our bodies, our health, and our world. Ara previously co-founded and served as CMO of mobile commerce marketplace, Spring (backed by LMVH, sold to ShopRunner), and was on the founding team of social commerce company, BeachMint (sold to Conde Nast), where she launched six direct-to-consumer, influencer subscription brands. She is an angel investor and advisor in companies such as mindbodygreen, Stadium Goods (recently sold to FarFetch), RXDefine, women’s healthcare startup, Mahmee, and new biomaterials company, C16. Ara has been a fellow at the MIT Media Lab’s Center for Future Storytelling and CCA’s Design MBA program, was named in Marie Claire’s “The New Guard: The 50 Most Influential Women in America”, listed on Business Insider’s “Silicon Alley Top 100” and “36 Rockstar Women in NYC Tech”, and Create + Cultivate’s 100 List for STEM.
Follow Ara Katz:
About Seed Health: Seed Health is a microbial company that focuses on therapeutics, consumer health innovations, and environmental solutions.
Kevin Chan
Co-Founder of Headway
Follow Kevin Chan:
About Headway, Maderight: Headway is a mental healthcare system provider that helps patients connect with therapists and submit insurance claims online.
Dr. Jon Einarsson
Founder & Inventor of Lattis Surgical
Follow Dr. Jon Einarsson:
About Harvard Medical School, Lattis Surgical: The Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology.
Alexander Isakov
Founder & CEO of Lattis Surgical
Follow Alexander Isakov:
About Lattis Surgical: The Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology.
Jordan Smith
Founder & Board of Directors of Lattis Surgical
Follow Jordan Smith:
About Lattis Surgical: The Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology.
Gregory Winter
Scientific Founders of Bicycle Therapeutics
Professor Sir Gregory Winter is a member of the Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge and most of his scientific career was based there. He was Head of Division of Protein and Nucleic Acid Chemistry, succeeding Cesar Milstein and has served as both Deputy and Acting Director of the LMB. He is a Fellow of the Royal Society, was knighted in 2004 for services to science and in 2012 was appointed by the Queen as Master of Trinity College, Cambridge. Sir Gregory is a graduate of University of Cambridge (1973), specialising in chemistry and biochemistry; for his PhD (1976) and postdoctoral work (1977-1981) he specialised in protein and nucleic acid sequencing respectively and with colleagues determined the genome sequence of influenza virus. From 1982 he pioneered the science of protein engineering, focusing first on enzymes (with A. Fersht) and then antibodies. He invented techniques to humanise rodent antibodies for use as therapeutics (1986–), working with H. Waldmann in the development of alemtuzumab/Campath-1H. Later, in competition with R. Lerner, he developed methods to make fully human antibodies (1989–) against human self-antigens using antibody libraries. His inventions are used in most of the antibody products on the market, including the humanised antibodies alemtuzumab/Campath-1H, trastuzumab/Herceptin, bevacizumab/Avastin, palivizumab/Synagis and the first human antibody (adalimumab/Humira) to be approved by the US FDA. Sir Gregory has acted as an entrepreneur to translate his scientific inventions to medicines. He was a founder of Cambridge Antibody Technology (CAT,1989) and Domantis (2000); these companies pioneered the use of antibody libraries to make fully human antibody therapeutics. CAT was floated on the London Stock Exchange in 1997 and was responsible for the co-development of the therapeutic antibodies adalimumab/Humira and belimumab/Benlysta. CAT was acquired by AstraZeneca in 2006. Domantis developed a range of product leads based on single antibody domains and was acquired by GSK in 2006 in a private sale. Sir Gregory has won several international scientific prizes, including the Prix Louis Jeantet de Medecine (Switzerland) in 1989; the King Faisal International Prize for Medicine (Molecular Immunology, Saudi Arabia) in 1995; the Biochemical Analysis Prize of the German Society for Clinical Chemistry in 1995; the Cancer Research Institute William B. Coley Award (US) in 1999; and the Royal Medal of the Royal Society in 2011. For his work with industry, he received the National Biotechnology Ventures Award (US) in 2004 and the BioIndustry Association Award (UK) in 2008. In March 2013 he was awarded the Gairdner Prize for the engineering of humanised monoclonal antibodies and their widespread use in medical therapy, particularly for treatment of cancer and immune disorders.
Follow Gregory Winter:
About Ahren Innovation Capital, Bicycle Therapeutics, MRC Laboratory of Molecular Biology, Trinity College, Dublin: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Christian Heinis
Scientific Founders of Bicycle Therapeutics
Christian Heinis is Scientific Founders at Bicycle Therapeutics.
Follow Christian Heinis:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Paul Chang
President, CEO/CSO and Lead Founder of ARase Therapeutics
Follow Paul Chang:
About ARase Therapeutics: Arase Therapeutics is a science-focused oncology company developing therapies that modulate cancer-relevant cell signaling pathways.
Eric Fischer
Co-Founder of Civetta Therapeutics
Eric Fischer is the Founder at Neomorph.
Follow Eric Fischer:
About Civetta Therapeutics, Neomorph: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
William Sellers
Co-Founder of Civetta Therapeutics
William Sellers is the Co-Founder of Civetta Therapeutics.
Follow William Sellers:
About Civetta Therapeutics: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
Mike McSherry
CEO & Founder of Xealth
CEO at Xealth.
Follow Mike McSherry:
About Xealth: Xealth is a platform for digital health, enabling clinicians to prescribe and monitor digital tools from within the EHR workflow.
Eric Fu
Co-Founder and CTO of Xealth
Eric Fu is Co-d=founder and Chief Technology Officer at Xealth. Before this, he was with Providence Health & Services as resident entrepreneur. He was director of engineering at Nuance Communications as well.
Follow Eric Fu:
About Xealth: Xealth is a platform for digital health, enabling clinicians to prescribe and monitor digital tools from within the EHR workflow.
Daniel Perez
Co-Founder, CEO of Hinge Health
With a long personal history of MSK injuries including several leg surgeries, Dan has long been passionate about improving outcomes for musculoskeletal disorders. Originally from Miami, Dan pursued a PhD in the medical sciences at the University of Oxford (currently paused), founding the Oxbridge Biotech Roundtable and OneStart, a large healthcare accelerator program. As CEO, Dan brings startup technology experience and healthcare expertise to Hinge Health.
Follow Daniel Perez:
About Hinge Health: Hinge Health is a patient-centered digital clinic for treating chronic musculoskeletal conditions.
Nichola Eliovits
Co-Founder, Chief Business Officer of DermBiont
Nick’s investment expertise spans across asset classes with an extensive focus on microbiome oriented companies across all stages of venture capital. Nick is a Managing Partner at Olive Tree Capital; he led his last company through acquisition and has successfully seeded and structured companies across multiple industries. His passion for the Microbiome originates from personal experiences with skin infections and c-diff. Nick graduated with honors from Boston University’s Questrom School of Business and started his career in commodity markets at CPM Group in New York.
Follow Nichola Eliovits:
About DermBiont, Popover: DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases.
Geraldine Harriman
CSO & Co-Founder of HotSpot Therapeutics
Geraldine Harriman is the Co-Founder and Chief Scientific Officer of HotSpot Therapeutics.
Follow Geraldine Harriman:
About HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Mark McManus, Jr
Founder and Chairman of The Healing Notes Foundation
Mark McManus, Jr. is President and Chief Executive Officer at NH Learning Solutions. A veteran of the computer training industry for more than 20 years, Mark is responsible for the company’s vision, financial performance, personnel, and organizational development. He has received a variety of awards in recognition of his numerous accomplishments. He was awarded the prestigious New Horizons President’s Cup award in 1997, the Circle of Excellence in 2000, and the New Horizons Lifetime Achievement Award in 2007. He has also received 10 North American “Franchise of the Year” awards over the past 15 years for the business performance within the Detroit, MI market. In addition, he was named one of Crain’s Detroit Business’ “40 under 40” in 1998, which recognized young, successful executives in Michigan. Mark is a member of the Young Presidents Organization Greater Detroit Chapter, as well as a member of the Franchise Advisory Committee (FAC) for New Horizons Computer Learning Centers.
Follow Mark McManus, Jr:
About Intellezy, NHLearning Solutions, The Healing Notes Foundation: The Healing Notes Foundation helps children and families cope with sickness and hospitalization by providing music therapy services.
Cheng Liu
Founder, CEO of Eureka Therapeutics
Cheng Liu is the founder and CEO of Eureka Therapeutics, a California biotech company dedicated to antibody research and discovery for cancer immunotherapy. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.
Follow Cheng Liu:
About Eureka Therapeutics: Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Michael M. Henson
Founder of Endologix
Michael Henson is a co-founder of Reverse Medical Corporation, was named “Corporate Director of the Year” among all Orange County executives in 2000. He founded the MedFocus Fund with the Japan Asia Investment Company, Ltd., one of the largest venture capital firms in Japan and a group of international limited investors from around the world. Mr. Henson has participated in the formation of more than seventeen medical technology and pharmaceutical firms. He currently serves on the Board of Directors of nine medical firms, and is Chairman of seven of the companies. Mr. Henson has founded or served as Chief Executive Officer and Chairman of the Board for many successful emerging health care, medical device or biotechnology firms. Mr. Henson has successfully taken a number of companies public via the IPO process and negotiated the successful acquisition of several emerging companies to large multi-national healthcare firms.
Follow Michael M. Henson:
About Endologix, Interventional Spine, Reverse Medical: Endologix is a developer and manufacturer of minimally invasive treatments for aortic disorders.
Amit Vohra
Co-Founder, President & CEO of Promaxo
Promaxo is led by Dr. Amit Vohra who is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. Amit is a Partner in Advanced Biopharma Consulting, a management consultancy offering strategic business development and commercialization services in the life sciences space. He also serves as an advisor to Cricking, MedDx and HealthyX and a strategy consultant to Precision Biopsy and Weinberg Medical Physics. Prior to Promaxo, Amit was the CEO/President of Convergent Life Sciences wherein he took a MRI-US fusion product, for targeted laser ablation of soft tissue cancer, through FDA clearance within 18 months of Company formation. Previously, as VP of Strategy and Operations at Eigen, he led the development and successful commercialization of two class II medical devices in the prostate biopsy space. In 2009, Amit co-founded Navya Biomedical Technologies, a biotechnology company using proprietary polyhydroxy fullerenes (PHF) for non-invasive imaging and destruction of solid tumors. Amit has a Doctorate in Mechanical Engineering from University of Florida, and an Executive MBA (Fuqua Scholar) from Duke University’s Fuqua School of Business.
Follow Amit Vohra:
About 8chili, Neuro42, Promaxo, TriOcula Technologies: Promaxo is commercializing customer-centric MRI systems and robotic guidance tools for live diagnosis and treatment in a physician’s office.
Michael Bartholomew
Co-Founder, Inside Director & Chief Commercial Officer of Promaxo
Mr. Michael Bartholomew is the EVP and Chief Commercial Officer at Promaxo. He has broad therapeutic experience across nearly twenty diseases covering large and small molecules, medical devices and diagnostics. Michael manages the go to market strategy, voice of customer, partner relationships and tactical implementation relating to corporate infrastructure. Prior to Promaxo, Michael was a Principal at Porzio Life Sciences, as well as Vice President of Sales & Marketing for Dohmen Life Science Service, where he developed and launched several commercial initiatives achieving sustained sales growth. Before Dohmen, he served in various sales and brand leadership positions for Pfizer, Pharmacia and Baxter. Michael proudly served in the US Air Force as a decorated combat aviator, where he achieved the rank of Captain. He received his Masters of Science in Administration from Central Michigan University and his Bachelor of Arts in Economics from Indiana University.
Follow Michael Bartholomew:
About Neuro42, Promaxo: Promaxo is commercializing customer-centric MRI systems and robotic guidance tools for live diagnosis and treatment in a physician’s office.
Harry Gruber
CEO, Co-Founder & President of Tocagen
Harry E. Gruber, M.D., one of the pioneers in gene therapy, co-founded Tocagen and led the company as chief executive officer before assuming the role of president, research and development in November 2016 and president, science and innovation in October 2017. He has been a member of the board of directors since August 2007. Dr. Gruber served as our chief executive officer from August 2007 to November 2016 and served as chairman of our board of directors from August 2007 to October 2014. Dr. Gruber is a co-founder of Tocagen and has been the co-founder and/or co-inventor of key technology for the following publicly held companies: Viagene Inc., a gene therapy company acquired by Novartis Pharmaceuticals; Gensia Inc., a biopharmaceutical company acquired by Teva Pharmaceuticals Industries, Ltd.; INTERVU Inc., a technology company acquired by Akamai Technologies, Inc.; Kintera, Inc., a technology company acquired by Blackbaud. He is the author of more than 100 original scientific articles and an inventor on more than 100 issued and pending patents. Dr. Gruber holds a medical degree and bachelor’s degree from the University of Pennsylvania and trained in Internal Medicine, Biochemical Genetics and Rheumatology/Immunology at the University of California, San Diego, where he subsequently joined the medical school faculty until founding Gensia Inc.
Follow Harry Gruber:
About Tocagen: Tocagen is a biopharmaceutical company developing gene therapy products for the treatment of cancer.
Igor Khandros
Co-Founder of Berkeley Lights
Igor Y. Khandros Co-Founded Berkeley Lights, Inc. and serves as its Chief Executive Officer. Igor Khandros served as an Advisor of FormFactor Inc. Igor Khandros founded Formfactor Inc. and served as its Executive Chairman. Igor Khandros served as the Chief Executive Officer of Formfactor and also served as its President Igor Khandros served as the Vice President of Development of Tessera Technologies Inc., that he co-founded. he was employed at the Yorktown Research Center of IBM Corporation as a Member of the Technical Staff and a Manager. Igor Khandros was employed at ABEX Corporation as a Research Metallurgist and a Manager, and he served as an Engineer at the Institute of Casting Research in Kiev, Russia. Igor Khandros has been a Director of FormFactor Inc., Igor Khandros holds an M.S. equivalent degree in Metallurgical Engineering from Kiev Polytechnic Institute in Kiev, Russia, and a Ph.D. in Metallurgy from Stevens Institute of Technology.
Follow Igor Khandros:
About Berkeley Lights, Nutcracker Therapeutics: Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Michel Sadelain
Scientific Co-Founder of Juno Therapeutics
Dr. Michel Sadelain is Head of the Gene Transfer and Gene Expression Laboratory at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr. Sadelain’s research focuses on novel approaches to enhance T cell costimulation and function. His clinical program focuses on B cell malignancies as well as solid tumors. Dr. Sadelain is the incumbent of the Stephen and Barbara Friedman Chair and the founding director of the Center for Cell Engineering at MSKCC. He previously served on the board of directors of the American Society of Gene Therapy (2004-2007) and continues to serve on the editorial boards of Molecular Therapy, Human Gene Therapy and Gene Therapy.
Follow Michel Sadelain:
About Juno Therapeutics: Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Isabelle Rivière
Scientific & Co-Founder of Juno Therapeutics
Isabelle Rivière received her Ph. D. in Cellular and Molecular Biology from the University of Paris in 1993. She initiated her graduate studies in the Interferon Research Group at the Institut Curie, Paris and completed her thesis work in the laboratory of Richard Mulligan,Ph.D at the Whitehead Institute for Biomedical Research, Cambridge, MA. During this time, she developed the MFG/SFG-based gamma-retroviral vectors for in vivo long-term expression of transgenes in hematopoietic cells, which are currently used in multiple clinical trials for the treatment of hereditary blood disorders and cancer. She subsequently worked as a postdoctoral fellow in the laboratory of Dan Littman, MD, Ph.D at New York University, New York, NY. Her studies focused on the regulation of cytokines produce by T helper lymphocytes in vivo, based on a mouse model she developed to track IL-4 secreting T cells using homologous recombination in embryonic stem cells. Dr. Rivière joined the faculty of the Memorial Sloan-Kettering Cancer Center (MSKCC) in 1999. She is currently the Director of the Cell Therapy and Cell Engineering Facility where she investigates novel strategies for cell therapies and immunotherapies to increase or retarget the immune response against tumors and treat hematological disorders. Her laboratory has developed multiple processes for clinical-grade gamma-retroviral and lentiviral vector production as well as hematopoietic and T cell manufacturing. Dr. Rivière serves on the editorial board of Molecular Therapy: Methods and Clinical Development and on multiple committees of the Association of Academic Biologics Manufacturers (AABM), the International Society for Cellular Therapy (ISCT) and the American Society of Gene & Cell Therapy (ASGCT).
Follow Isabelle Rivière:
About Juno Therapeutics: Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Stan Riddell
Scientific Co-Founder of Juno Therapeutics
Stan Riddell is a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and Professor of Oncology at the University of Washington School of Medicine. Dr. Riddell is a leader in developing therapies that harness the immune system to fight cancer and infectious diseases. His research led to patented technologies that rapidly expand the number of disease fighting T cells used in adoptive immunotherapy. He also isolated a rare subset of disease-fighting T cells that survive in patients for an extraordinary amount of time. In 2010, Dr. Riddell received the International Society for Biological Therapy of Cancer’s first Team Science Award for major contributions to research and the clinical translation of cancer immunotherapy. Dr. Riddell received his M.D. from the University of Manitoba in Winnipeg. He joined FHCRC Faculty in 1991 after training in medical oncology and immunology. Dr. Riddell was recently elected to the Association of American Physicians, an organization honoring those who have achieved excellence in biomedical science.
Follow Stan Riddell:
About Juno Therapeutics, University of Washington: Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Vivek Kopparthi
CEO, Co-Founder & Executive Chairman of NeoLight
Vivek Kopparthi is Co-founder & CEO of NeoLight, a lean medical device start-up developing a disruptive technology to treat Jaundice in infants.
Follow Vivek Kopparthi:
About NeoLight, PriZm Therapeutics: Neolight is a medical device company that develops phototherapy beds to cure jaundice in pre-term and full term babies.
Stephen Smith
Co-Founder of Pear Therapeutics
Stephen Smith received his B.A from Harvard University, J.D. from Columbia University, and M.Ed from Harvard University School of Education. After law school, Stephen served as an assistant district attorney in New York. He later joined the staff of the Senate Judiciary and Foreign Relations Committees. After leaving the Senate, Stephen worked at Conflict Management Group; a nonprofit associated with Harvard Law School, and taught in the advanced program on negotiation at Harvard University Law School. As part of his work at Conflict Management, Stephen consulted with global clients including the Organization of African Unity, the World Bank, the Inter-American Development Bank and the parties in the Irish Peace process. Stephen is a three-time recipient of the Danforth Award for excellence in teaching at Harvard University and is also the winner of the Lyndehurst Foundation Prize for social and artistic achievement. For the past twenty years, Stephen has been on the Kennedy board of Joseph P. Kennedy Enterprises, the Kennedy family investment office. He has delivered keynote presentations at the annual conferences of the Family Firm Institute and the Family Office Exchange– the two major family business organizations. Stephen has also served on the board of the John F. Kennedy Library, the Robert F. Kennedy Memorial, Citizens Energy, the Northeastern University School of Public Policy, and INCAE Business School and the advisory board of the Joslin Diabetes Center at Harvard Medical School. Stephen is a Fellow at the International Economic Alliance, an organization dedicated to promoting innovative international trade. As a partner and board member, Stephen is actively involved in a number of medical and green technology businesses, including Emlink, which develops, designs and manages sustainable technology; The Marwood Group, a healthcare-focused strategic advisory and financial services firm; and Pear Therapeutics, a medical software company. Stephen was Deputy Campaign Manager for Senator Edward Kennedy during his Presidential and Senatorial campaigns, Youth Coordinator for the campaign of Mario Cuomo, served on the New England Steering Committee for the Obama presidential campaign, and continues to be active in Democratic politics.
Follow Stephen Smith:
About Pear Therapeutics: Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Shantanu Gaur
Co-Founder & CEO of Allurion Technologies
Shantanu Gaur co-founded Allurion in 2009 during his second year at Harvard Medical School and is our Chief Scientific Officer. A Paul & Daisy Soros Fellow, Shantanu graduated summa cum laude and Phi Beta Kappa from Harvard College with an S.B. in Biology and significant coursework in polymer chemistry. Shantanu graduated from Harvard Medical School in 2013. He grew up in Pittsburgh, Pennsylvania and lives in Cambridge, Massachusetts.
Follow Shantanu Gaur:
About Allurion Technologies, Genetic Alliance: Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
Steven McKnight
Founder of Peloton Therapeutics
Follow Steven McKnight:
About Flare Therapeutics, Peloton Therapeutics, Tularik, University of Texas Southwestern Medical School: Peloton Therapeutics, a biotech company based in Dallas, is involved in discovering and developing novel drugs for cancer treatments.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Greg Verdine
Co-Founder, President & CEO, CSO of LifeMine Therapeutics
Greg Verdine is the Founder of Gloucester Marine Genomics Institute & he attended Massachusetts Institute of Technology in 1986.
Follow Greg Verdine:
About FogPharma, Gloucester Marine Genomics Institute, Harvard Medical School, Harvard University, LifeMine Therapeutics, Massachusetts Institute of Technology, Wave Life Sciences: Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology.
Jerry Bryant
Founder, Managing Member & CTO of Cell Point
Jerry Bryant, Jr., is a founding member of Cell>Point, the CTO and has been providing financial support to the company since its beginning. Mr. Bryant is also President and Managing Member of Vyripharm Biopharmaceuticals, a majority owned subsidiary of Cell>Point. Mr. Bryant brings 15 years in research experience in molecular biology, imaging and oncology. Prior to the establishment of Cell>Point, Mr. Bryant worked as a research assistant from 1994 through 1999 in the Department of Medicine, Division of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center. During 1999 and 2000, Mr. Bryant served as President of Allcure JEMA, Inc. Mr. Bryant received his B.S. from Tennessee State University in 1987 and M.S. from the University of Florida in 1991.
Follow Jerry Bryant:
About Cell Point: Cell Point is a biotechnology company developing universal molecular imaging agents and intra-nuclear metallic therapeutics.
Terry Colip
Founder, Managing Member & CFO of Cell Point
Terry Colip, the Founder of Cell>Point, was a founding member of the firm and has provided his expertise from its inception. Mr. Colip has 26 years of expertise in investment banking and venture capital in the healthcare industry. Prior to founding Cell>Point, Mr. Colip worked as a healthcare consultant for Coopers & Lybrand in New York. He provided equity and investment banking services for roughly $2 billion in healthcare transactions at Underwood Neuhaus & Co., Boettcher & Co., and American Health Capital, Inc. Mr. Colip was also a founding partner in Chewton Glen Energy L.L.C. This company built two electric power plants in Illinois. Many media outlets, including Fox Business Network, Fox News, NBC News Denver, ABC News Denver, CBS News Denver, and National Public Radio, have highlighted Mr. Colip. Mr. Colip earned a B.S.I.E. in 1979 from the University of Wisconsin’s College of Engineering and an M.P.A. in finance and healthcare administration from New York University in 1981. Mr. Colip donates his time and resources to charities and organizations that focus on healthcare and disability outreach.
Follow Terry Colip:
About Cell Point: Cell Point is a biotechnology company developing universal molecular imaging agents and intra-nuclear metallic therapeutics.
Greg Colip
Founder, Managing Member & CEO of Cell Point
Since its beginning, Greg Colip is a founding member of Cell>Point and has provided financial support to the company. Mr. Colip brings over 38 years of experience in healthcare marketing and legal. Prior to establishing the company with Jerry Bryant and Terry Colip, Mr. Colip was a corporate mergers and acquisition lawyer and served as Deputy General Counsel for Panhandle Eastern Corporation (which has since been split up with part of the company’s subsidiaries owned by Duke Energy and the remaining part-owned by CMS Energy), provided legal counsel and development work for various independent power projects, served as Vice President and General Counsel for the Gulfco Division of Chromalloy American Corporation and was a production/marketing manager for The Upjohn Company (now part of Pharmacia). At Panhandle Eastern, Mr. Colip was involved in numerous complex venture, merger, spin-off, and acquisition transactions, including the $2.4 billion acquisition of Texas Eastern Corporation and the $1.2 billion drop down and spin-off of Anadarko Petroleum Corporation. At Upjohn, Mr. Colip was the production/marketing systems manager for the corticosteroid and anticoagulant product lines. Mr. Colip received his bachelor’s degree in production management and industrial engineering in 1970, followed by his M.B.A. two years later and a J.D. in 1978. His higher education was at Indiana University, and Greg is proud to call it his Alma Mater.
Follow Greg Colip:
About Cell Point: Cell Point is a biotechnology company developing universal molecular imaging agents and intra-nuclear metallic therapeutics.
Charles Gersbach
Co-Founder & Scientific Advisor of Locus Biosciences
Dr. Charles A. Gersbach is the Rooney Family Associate Professor of Biomedical Engineering at Duke University, as well as the Director of the Duke Center for Biomolecular and Tissue Engineering. He also has appointments in the Duke University Medical Center in the Department of Orthopaedic Surgery and the Center for Genomic and Computational Biology. His research interests are in the areas of genome and epigenome editing, gene therapy, biomolecular and cellular engineering, regenerative medicine, synthetic biology, and genomics. Dr. Gersbach received his Bachelor’s degree in Chemical Engineering from the Georgia Institute of Technology and his Ph.D. in Biomedical Engineering from the Georgia Institute of Technology and Emory University School of Medicine focusing on the genetic reprogramming of adult stem cells for musculoskeletal tissue regeneration. Dr. Gersbach completed his postdoctoral training at The Scripps Research Institute in molecular biology and biochemistry, focusing on developing new genome editing tools with applications in biotechnology and gene therapy. Dr. Gersbach’s laboratory at Duke University is focused on applying molecular and cellular engineering to applications in gene therapy, regenerative medicine, and basic science. In particular, his research aims to develop new methods to genetically modify genome sequences and cellular gene networks in a precise and targeted manner. These new methods are then applied to correction of genetic diseases, directing stem cell differentiation, regeneration of damaged tissues, or answering fundamental biological questions regarding gene regulation and genome structure and function. Examples of technologies used in his research include genome and epigenome editing, protein engineering, directed evolution, genetic reprogramming, gene delivery, and optogenetics. Dr. Gersbach’s recognitions include the NIH Director’s New Innovator Award, the National Science Foundation CAREER Award, the Hartwell Foundation Individual Biomedical Research Award, the March of Dimes Basil O’Connor Scholar Award, and the Outstanding New Investigator Award from the American Society of Gene and Cell Therapy.
Follow Charles Gersbach:
About Element Genomics, Locus Biosciences, Tune Therapeutics: Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Dave Ousterout
Co-Founder & Chief Scientific Officer of Locus Biosciences
Dr. Dave Ousterout is a co-founder and Chief Technology Officer for Locus Biosciences. Dave’s expertise is in protein engineering and early stage applications of new technologies to treat human diseases. Dr. Ousterout earned a BS in Biological & Environmental Engineering from Cornell University, an MS in Biomedical Engineering from Duke University and a Ph.D. in Biomedical Engineering from Duke University. Dave completed his doctoral studies at Duke University in the lab of Dr. Charles Gersbach, where he developed novel gene editing approaches for correcting mutations that cause Duchenne muscular dystrophy. His other work has spanned across several fields, including designing and engineering viral and non-viral delivery vectors, DNA binding protein engineering and gene regulation. Prior to Locus, Dave was a consultant at McKinsey & Company.
Follow Dave Ousterout:
About Locus Biosciences: Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Paul Garofolo
Co-Founder, Chief Executive Officer, & Chairman of the Board of Locus Biosciences
Paul has been a member of multiple Executive Management teams of both publically traded multi-national corporations and successful startup opportunities. He currently serves as the CEO of Locus Biosciences, an emerging biotech focused on the discovery and development of a novel class of CRISPR/Cas Antimicrobials. Paul also serves as Vice President of the Friends Board at the North Carolina Museum of Natural Sciences, and as a Visiting Professor at North Carolina State University’s Poole College of Management. He serves as an executive-in-residence for the HiTEC Graduate Program, the University’s Entrepreneurship Collaborative.
Follow Paul Garofolo:
About Locus Biosciences: Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Chase Beisel
Co-Founder & Scientific Advisor of Locus Biosciences
Helmholtz Institute for RNA-based Infection Research (Germany) and North Carolina State University.
Follow Chase Beisel:
About Helmholtz Centre for Infection Research, Locus Biosciences, North Carolina State University – NCSU: Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Nick Taylor
Co-Founder & Project/Program Manager of Locus Biosciences
Follow Nick Taylor:
About Locus Biosciences: Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Mark McKenna
Founder, President and CEO of Prometheus Biosciences
Mark McKenna currently works as President and Chief Executive Officer at Prometheus Biosciences. He previously worked at Bausch + Lomb as Senior Vice President and General Manager.
Follow Mark McKenna:
About Prometheus Biosciences: Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.
Martyn Gross
Co-Founder & CEO of Zerigo Health
Advisor at Cooler Heads Care & Chief Business Officer at Mindera.
Follow Martyn Gross:
About Dthera Sciences, MiNDERA Corporation, Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Remo Moomiaie-Qajar M.D.
Co-Founder of Zerigo Health
Dr. Moomiaie-Qajar is a trained surgeon from Yale University with a long academic history of innovating technologies in medicine and translating them into commercially viable products. Dr. Moomiaie-Qajar has 15 years of experience incubating technologies from start-up or early stage level to exit. His background as an academic researcher, physician, and entrepreneur brings an unique trifecta of perspective and experience to Cytonus. He holds a number of US and International Patents and has successfully funded and launched a number of Life Science companies. He is the past CEO of Remo CRO, a full service CRO and Dr. Moomiaie-Qajar is an active member of a number of National Angel Investment Groups and manages a Life Science seed fund.
Follow Remo Moomiaie-Qajar M.D.:
About Remo Life Science, Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Remo Qajar
Co-Founder of Zerigo Health
Remo Qajar is the Co-Founder and Chief Innovation Officer at Skylit Medical. Remo’s postgraduate career as an academic researcher and trained Surgeon at the Yale School of Medicine led him to invent a number of medical devices, from implantable respiratory diaphragms to orthopedic and wound care products, some of which have been spun-off into companies. Remo is the founder of InQMEDS LLC. an accelerator of growth for early stage life-science products.
Follow Remo Qajar:
About Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Samuel D. Waksal
Founder & Chairman of MeiraGTx
Follow Samuel D. Waksal:
About Brain-Mind Institute, Graviton, MeiraGTx, Weill Cornell Medicine: Meira Gene Therapy is a clinical-stage company developing novel treatments for inherited and acquired genetic disorders.
Fabian Gerlinghaus
Co-Founder & CEO of Cellares
Fabian Gerlinghaus is the CEO and Co-Founder of Cellares.
Follow Fabian Gerlinghaus:
About Cellares: Cellares is a life sciences technology company that develops the Cell Shuttle to automate cell therapy manufacturing.
Douglas Mayers
Co-Founder and Chief Medical Officer of Antios Therapeutics
Mr. Douglas Mayers, M.D. serves as Co-Founder and Chief Medical Officer at Antios Therapeutics, Inc.
Follow Douglas Mayers:
About Antios Therapeutics: Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.
Josh Bilenker
Founder, President & CEO of Loxo Oncology
Josh Bilenker serves as a Partner of Aisling Capital. Previously, Josh Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Josh Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Josh Bilenker currently serves as a director of LensAR, Inc., Roka Bioscience, Inc., T2 Biosystems and ViewRay, Inc and as a board observer at Aragon Pharmaceuticals. He is also a Board Member of the NCCN Foundation and of BioEnterprise. Josh Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.Previously, Josh Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains a Venture Partner. From 2004-2006, Josh Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology. Josh Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Josh Bilenker received his M.D. from The Johns Hopkins School of Medicine. He received his A.B. from Princeton, awarded summa cum laude in English.
Follow Josh Bilenker:
About Aisling Capital, Loxo Oncology, Treeline Biosciences: Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.
Ravi Pamnani
CEO and Co-Founder of Intact Therapeutics
Ravi Pamnani is the CEO and co-founder of Intact Therapeutics. Prior to that, he served as a director of marketing and medical affairs for Transcend Medical. Ravi studied at Stanford University.
Follow Ravi Pamnani:
About Intact Therapeutics: Intact Therapeutics is a makers of smart gels for local drug delivery for gastrointestinal diseases.
James H. Bullard
Co-Founder and CTO of Pendulum Therapeutics
James Bullard is a Computational Biologist and Biostatistician with extensive experience in analyzing complex genomic systems. Prior to co-founding Whole Biome, Jim served as a Senior Staff Scientist at Pacific Biosciences. Jim, completed his Ph.D. in Biostatistics with a focus in Computational and Genomic Biology at the University of California, Berkeley and his B.A. in Computing and Information Systems at Northwestern University.
Follow James H. Bullard:
About Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Colleen Cutcliffe
Co-Founder and CEO of Pendulum Therapeutics
Colleen Cutcliffe is the Co-Founder and CEO of Pendulum Therapeutics.
Follow Colleen Cutcliffe:
About American Diabetes Association, California Life Sciences Association, Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
John S. Eid
Co-Founder and CSO of Pendulum Therapeutics
John Eid is a Biophysicist who has led fundamental technology development for over a decade. His research areas include advanced microscopy, single molecule detection and analyses, automated data acquisition system development, biophysical system modeling, genome sequencing applications and bioinformatics. Prior to co-founding Whole Biome, John served as a Principle Scientist at Pacific Biosciences. He joined the company shortly after it was founded and created, developed and applied its core sequencing technology from its incipient stages through commercialization. John completed his postdoctoral research at the Roland Institute at Harvard University, his Ph.D. in Biophysics and Computation Biology at the University of Illinois, Urbana Champaign, and his B.S. in Applied and Engineering Physics from Cornell University.
Follow John S. Eid:
About Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Mark Frank
Co-Founder & CEO of SonderMind
Mark Frank is the CEO and Co-Founder of SonderMind, which is redesigning behavioral health to be more accessible, approachable and utilized. The company provides a comprehensive solution for patients to receive high-quality therapeutic care, health plans and systems to address improving outcomes, and therapists to grow as clinicians and thrive in a private practice setting. Prior to SonderMind, Mark was the CEO and Founder of Next Oncology, a radiation oncology management services organization that he sold six years after founding. He was also the co-founder of SafeImageMD (sold in 2016), a SAAS solution for physicians and patients to manage medical imaging data. He is currently Chairman of the Board for an ACO-focused urgent care company, AfterOurs Inc. Mark graduated with a degree in Computer Science from West Point and served as an Army officer for five years, earning a Bronze Star during his time in Iraq. Following the Army, he earned both his MBA and Masters of Engineering Management at Northwestern University. Prior to his entrepreneurial efforts, Mark was an investment banker with Morgan Stanley, focusing on healthcare M&A. He is married with three extremely active elementary-school children
Follow Mark Frank:
About SonderMind: SonderMind is a digital health and telehealth company redesigning behavioral health to become more accessible, approachable, and utilized.
Sean Boyd
Co- Founder & Chief Clinical Officer of SonderMind
Sean Boyd is the Co-Founder of SonderMind.
Follow Sean Boyd:
About SonderMind: SonderMind is a digital health and telehealth company redesigning behavioral health to become more accessible, approachable, and utilized.
Robert Nicol
Co-Founder of HiFiBiO
Rob Nicol is director of the Technology Labs at the Broad Institute of MIT and Harvard. Under Rob’s guidance, the Technology Labs serve as an advanced R&D group within the institute integrating capabilities in molecular biology, bio-engineering, synthetic biology, microfluidics, bio-informatics, and industrial process design to meet the needs of the Broad community. Rob is also co-founder of the MIT-Broad Foundry for Synthetic Biology. Rob joined the Whitehead Institute / MIT Center for Genome Research in 2001 to apply industrial process design to genome sequencing and directed the Sequencing Operations and Technology Development groups at the Broad for over 12 years, designing and implementing multiple generations of high-throughput DNA sequencing processes. Earlier, as an MIT Leaders for Manufacturing Fellow, Rob worked on production line optimization for Raytheon’s AMRAAM missile and Boeing’s 777. Rob previously worked as a project manager for Fluor Corporation, where he managed multiple, large-scale petrochemical design and construction projects. Rob received his B.S. in mechanical engineering from the University of Houston, and an M.S. in chemical engineering, M.B.A., and Ph.D. in engineering systems from MIT.
Follow Robert Nicol:
About HiFiBiO: HiFiBiO provides proprietary single cell technologies for applications in drug and biomarker discovery and development.
David Wetherell
Founder & Managing Director of Biomark Capital
Follow David Wetherell:
About Biomark Capital: Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies.
Gibb Clarke
CEO and Co-Founder of Blockade Medical
Gibb Clarke is co-founder and CEO of Blockade Medical and has more than 10 years experience as a medical device executive with a specific focus on new technology development for the interventional neurovascular marketplace. Prior to co-founding Blockade, Gibb co-founded Pulsar Vascular, Inc. in 2006. A novel therapeutic approach for challenging and complex cerebral aneurysms. Gibb successfully raised multiple rounds of venture capital as well as helped craft and manage the clinical and regulatory strategy for both CE Mark and US approvals. Prior to Pulsar, Gibb played a critical early role in helping Swedish Medical Center in Seattle, WA, plan for and execute the development of The Seattle Neuroscience Institute, a neuroscience center for excellence. Gibb’s efforts resulted in Swedish Medical investing in excess of $35M into the development of its now flagship neuroscience center located in Seattle, WA. Gibb also spent 8 years in the US Marines Corps serving as a team leader in the elite Marine Recon unit. Military schoolings include Amphibious Recon Course, Army Ranger School, US Navy Dive School, and Army Jump School. Gibb is an avid endurance athlete, having competed in over 200 races.
Follow Gibb Clarke:
About Blockade Medical: Founded in 2011, Blockade Medical is a privately held company dedicated the development of catheter based therapeutic devices for the
Benjamin Cravatt
Director and Co-Founder of Boundless Bio
Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. Ben obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.
Follow Benjamin Cravatt:
About Boundless Bio, Vividion Therapeutics: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Jonathan Lim
Chairman & Co-Founder of Boundless Bio
Jonathan Lim is Founder of Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company that is a portfolio company of City Hill Ventures, LLC, a health care investment firm that he founded in 2010. Jonathan is also a Board Director of Bionomics Ltd (ASX: BNO). Prior to Ignyta, Jonathan’s experience includes Chairman, CEO and co-founder of Eclipse Therapeutics, Inc.; President and CEO of Halozyme Therapeutics, Inc. (Nasdaq: HALO); management consultant at McKinsey; NIH Postdoctoral Fellow at Harvard Medical School; and general surgery resident at New York Hospital-Cornell. In addition to serving on the Bio-X Advisory Council, Jonathan has been actively involved with his class reunion campaigns and other Stanford related activities. Jonathan has a B.S and M.S. from Stanford in Biological Sciences, an M.D. from McGill University and an M.P.H. from Harvard. Jonathan lives in San Diego with his wife, Dr. Conyee Tsai Lim (BA ’93), and their three children.
Follow Jonathan Lim:
About ARCH Venture Partners, Boundless Bio, City Hill Ventures, Erasca: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Amber Salzman
President & CEO & Co-Founder of AAVLife
Follow Amber Salzman:
About AAVLife, Ohana Biosciences, Stop ALD Foundation: AAVLife is a privately held company dedicated to advancing gene therapy for rare diseases.
Joseph Moskal
Founder & Chief Scientific Officer of Naurex
Joseph Moskal is chief scientific officer of Aptinyx. He founded Naurex and served as its chief scientific officer until the company was acquired by Allergan. He is also distinguished professor of biomedical engineering at Northwestern University and director of the university’s Falk Center for Molecular Therapeutics. Joseph Moskal previously served as assistant professor and director of the neurosurgery laboratories at the Albert Einstein College of Medicine. Earlier, he was a staff fellow at the National Institutes of Health. Joseph Moskal is well known for his research on the NMDA receptor. He received a B.S. and a Ph.D. from the University of Notre Dame.
Follow Joseph Moskal:
About Aptinyx, Molecular Therapeutics, Naurex, Northwestern University: Naurex is a clinical-stage company developing novel therapeutics for depression and other CNS disorders.
Andrea Choe
Founder & CEO of Holoclara
Follow Andrea Choe:
About Caltech, Holoclara: Holoclara is a immunotherapy company that offers autoimmune disorders with nematode derived molecules.
J. Jean Cui
Scientific Founder & Board Member of Turning Point Therapeutics
J. Jean Cui, Ph.D. is a renowned oncology drug designer with more than 20 years of experience in drug discovery and project management at Big Pharma and biotech companies (Pfizer, Pharmacia/SUGEN, etc.). Jean is the lead inventor of Pfizer’s precision oncology medicine, crizotinib, brand named XALKORI®. She created the drug’s novel chemical scaffold based on co-crystal structure and designed the final clinical compound crizotinib. XALKORI® was fast track approved by US Food and Drug Administration on August 26, 2011 for ALK positive late stage non-small cell lung cancer (NSCLC). In addition to the invention of crizotinib, Jean worked on several other oncology projects, including SUTENT®. She also created the clinical c-MET specific inhibitor PF-04217903 and designed the ALK second generation clinical compound PF-06463922. Her exceptional achievements in drug discovery and development have earned her many prestigious awards which include: the 38th National Inventor of the Year by Intellectual Property Owners’ Association (2011); Woman Worth Watching by Diversity Journal (2012); American Chemical Society Hero of Chemistry (2013); Pfizer Worldwide R&D Achievement Awards (2006 and 2012); Pfizer Innovation Award (2011); CABS K. Fong Award for Life Sciences (2013). Her story of crizotinib invention was featured in a Wall Street Journal article titled “Drug Discovery Gets an Upgrade” on April 16, 2012.
Follow J. Jean Cui:
About BlossomHill Therapeutics, Turning Point Therapeutics: Turning Point Therapeutics is a structure-based drug design pharmaceutical company.
Konstantin Mehl
CEO, Founder & President of Kaia Health
Konstantin is a serial entrepreneur. His last company foodora, a global food delivery company was sold to delivery hero in 2015 after reaching 500 employees and 5,000 drivers. His current company Kaia has the mission to build the biggest platform for chronic disease management, powered by computer vision. His angel investments include more than 20 companies in the US and Europe. He holds a dual Masters from Columbia University and a Bachelors degree from Technical University Munich.
Follow Konstantin Mehl:
About Kaia Health, Kaia Health: Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of medical disorders.
John Kuriyan
Co-Founder of Nurix Therapeutics
John Kuriyan, Ph.D., is an expert in the structural dynamics of ubiquitin ligases and other signaling complexes. Dr. Kuriyan is a Howard Hughes Medical Institute Investigator and a Professor of Molecular and Cell Biology and of Chemistry, University of California, Berkeley. Prior to that, he served as Assistant Professor and then Professor at Rockefeller University for 14 years. Dr. Kuriyan serves as a member of the Advisory Board at Carmot Therapeutics Inc. and is a Senior Editor at eLife, a new enterprise in high profile and open access scientific publishing. He is a member of the National Academy of Sciences, which awarded him the 2005 Richard Lounsbery Award. He holds a B.S. in chemistry from Juniata College, Pennsylvania, and a Ph.D. from the Massachusetts Institute of Technology.
Follow John Kuriyan:
About Nurix Therapeutics: Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Arthur Weiss
Co-Founder of Nurix Therapeutics
Arthur Weiss, M.D., Ph.D., is a pioneer in cell biology and signal transduction. Dr. Weiss is a Howard Hughes Medical Institute Investigator and Ephraim P. Engleman Distinguished Professor, University of California San Francisco. He has previously served as the President of the American Association of Immunologists. He was also elected to the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine. Dr. Weiss received his B.A. at the Johns Hopkins University and his M.D. and Ph.D. from the University of Chicago School of Medicine. He did postdoctoral training at the Swiss Institute for Experimental Cancer Research and his clinical training in internal medicine and rheumatology at UCSF.
Follow Arthur Weiss:
About Nurix Therapeutics, University of California, San Francisco, University of California, San Francisco: Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Michael Rape
Co-Founder of Nurix Therapeutics
Michael Rapé, Ph.D., is a leader in the biology of ubiquitin-dependent cell cycle progression and carcinogenesis. He is a Howard Hughes Investigator and a Professor of Cell and Developmental Biology at the University of California, Berkeley. He started his own lab at the University of California, Berkeley in the fall of 2006, where he has developed novel screening tools to identify the ubiquitylation enzymes that are important for cell division and differentiation and pair them with the proteins they target. Prior to that, he completed his postdoctoral research at Harvard Medical School in the lab of Marc Kirschner. In recognition of his creativity and productivity, Dr. Rapé was named a Pew Scholar and received the NIH Director’s New Innovator Award in 2007. He has also won prestigious fellowships from the Human Frontier Science Program and the European Molecular Biology Organization. Dr. Rapé studied Biochemistry at the University of Bayreuth in Germany and received his Ph.D. at the MPI in Martinsried, Germany in the lab of Stefan Jentsch.
Follow Michael Rape:
About Nurix Therapeutics: Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Anand Parikh
Founder & CEO of Faeth Therapeutics
Follow Anand Parikh:
About Faeth Therapeutics, Virta Health: Faeth Therapeutics is a data-driven company that focuses on using metabolism to rethink the science of cancer.
George Hillman
COO, VP & Co-Founder of Viracta Therapeutics
George Hillman is the Co-Founder, Chief Operating Officer, and Vice President of Viracta Therapeutics.
Follow George Hillman:
About Viracta Therapeutics: Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.
Alex Katz
Founder and CEO of Two Chairs
Follow Alex Katz:
About Two Chairs: Two Chairs provides high-quality, in-person psychotherapy at thoughtfully-designed clinics.
Juan Jaen
President & Co-Founder of Arcus Biosciences
Juan has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Juan led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. At ChemoCentryx, Juan led the discovery efforts for the multi-year collaboration with GSK, which generated over $100M in non-dilutive milestones and fees. From 1996 to 2006, Juan held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry. From 1983 to 1996, Juan held various scientific leadership positions at Parke-Davis/Warner-Lambert. Juan holds a Visiting Scholar appointment (ChEM-H) at Stanford University and is a member of the Scientific Advisory Board at Cleave Biosciences. Juan obtained a B.S. degree in Chemistry from Universidad Complutense in Madrid (Spain) and a Ph.D. degree in Organic Chemistry from the University of Michigan. He has co-authored over 100 scientific papers and is an inventor on 50 issued U.S. patents. Juan has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma, and vasculitis, among others.
Follow Juan Jaen:
About Arcus Biosciences: Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Jay Bradner
Co-Founder of C4 Therapeutics
Jay Bradner, MD. President, Novartis Institutes for Biomedical Research, effective March 1, 2016. Former Associate Professor, Harvard Medical School. Co-founder of SHAPE Pharmaceuticals, Acetylon Pharmaceuticals, Tensha Therapeutics, and Syros Pharmaceuticals. First to accomplish an all-chemical strategy for target-specific protein degradation (Science, 2015).
Follow Jay Bradner:
About Acetylon Pharmaceuticals, Broad Institute, C4 Therapeutics, Novartis Institutes, Shape Pharmaceuticals, Syros Pharmaceuticals, Tensha Therapeutics: C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Kevin Connors
Executive Director, Founder of Solace Therapeutics
Kevin Connors is an accomplished entrepreneur and venture investor. He has co-founded seven healthcare technology companies, and has had interim CEO roles in nine. These companies have focused on developing proprietary technology to address large un-met medical needs, such as emphysema, low back pain, cerebral aneurysm, and bladder dysfunction. Prior to founding Spray Venture Partners in 1996, Kevin was the founding CEO of Vesica Medical, a company focused on the surgical treatment of female urinary incontinence. Under this leadership, Vesica realized product sales within 18 months of formation and was acquired by Boston Scientific Corporation in 1995. Prior to Vesica, Kevin led medical device investment activity at DSV Partners in Newport Beach, California. Kevin is on the Board of Directors of the New England Venture Capital Association and MassMEDIC, the Massachusetts Medical Device Industry Council. He has served on the Board of Directors of Vesica Medical, Inc. (acquired by Boston Scientific), Masimo Corp., Pilot Cardiovascular (acquired by CR Bard), Circe Biomedical (acquired by ICN Pharmaceuticals), Gamera Bioscience (acquired by Tecan AG), and Endonetics (acquired by Medtronic). In addition to serving on our board, he also serves on the boards of, Facet Solutions, Leptos Biomedical, Solace Therapeutics, Highgate Orthopedics, and Cascade Ophthalmics. Kevin received a B.S. in Electrical Engineering from the University of Notre Dame, an M.S. in Electrical Engineering from the University of Dayton, and an M.B.A. from the Harvard Business School.
Follow Kevin Connors:
About AgenDx Biosciences, Solace Therapeutics, Spray Venture Partners: Solace Therapeutics develops and commercializes non-surgical office-based treatments for common bladder disorders.
Dan Janiak
Co-Founder of Apsara Therapeutics
Danny Janiak is an Associate with the Mercury Fund, where he focuses on developing and originating science-based investment themes and startup opportunities. Prior to joining Mercury, Danny was an Associate in the Physical and Biological Technologies practice at In-Q-Tel, the strategic venture investment arm of the U.S. Intelligence Community. While at In-Q-Tel, Danny was responsible for the management and oversight of technology development programs in numerous In-Q-Tel portfolio companies. In addition, he was responsible for leading technical due diligence on all potential investment candidates in the advanced materials space. Danny received his B.S. and Ph.D. from the University of Maryland where he was a Future Faculty Fellow and held the Robert E. Fischell Fellowship in Biomedical Engineering. In addition, Danny has been selected to participate in the Kauffman Fellows Program through the Center for Venture Education.
Follow Dan Janiak:
About Apsara Therapeutics: Apsara Therapeutics develops antibody therapies for the treatment of neuromyelitis optica.
Jen Nwankwo
Founder, CEO of 1910 Genetics
Jen Nwankwo is the Founder and CEO at 1910 Genetics.
Follow Jen Nwankwo:
About 1910 Genetics: 1910 Genetics is a biotechnology company integrating AI, computation, and biological automation to improve drug development.
Mattan Griffel
Co-Founder/President & COO of Ophelia
Mattan is an award-winning faculty member at Columbia Business School and a two-time Y Combinator-backed entrepreneur. He co-founded Ophelia, a company that helps people quit opioids without having to go to rehab. Mattan is also an Innovation Fellow at the Lang Center for Entrepreneurship and was selected as one of Forbes’ 30 Under 30 in Education.
Follow Mattan Griffel:
About One Month | Learn to Code in 30 Days, Ophelia, Sandbox Network: Ophelia offers medication and support for quitting opioids.
Zack Gray
Co-Founder & CEO of Ophelia
Zack Gray is the Founder and CEO at Ophelia .
Follow Zack Gray:
About Ophelia: Ophelia offers medication and support for quitting opioids.
David Benshoof Klein
Founder & CEO of Click Therapeutics
David Benshoof Klein is a healthcare investor and entrepreneur with over 13 years life science industry experience; he has played key roles in founding, financing and developing more than 10 life science companies. In 2012, Mr. Klein co-founded Click Therapeutics, Inc. which focuses on engineering, validating and commercializing Digital Therapeutics™ applications to benefit people with brain disorders and neuropsychiatric dysfunction. He formerly served as Managing Director at a life science asset management firm & senior consultant to Pfizer.
Follow David Benshoof Klein:
About Click Therapeutics: Click Therapeutics delivers safe and effective digital treatments to patients in need.
Suresh Jain
Co-Founder, President & COO of Acylin Therapeutics
Follow Suresh Jain:
About Acylin Therapeutics: Acylin Therapeutics operates in the pharmaceutical and drug manufacturing industry developing inhibitors of cellular acetylation.
Robert J. Hariri, M.D., Ph.D.
Founder, Chairperson, and Chief Executive Officer of Celularity
Robert J. Hariri joined us as a Director in July 2011 and was elected Chairman of the Board in April 2012. Robert Hariri has served as the chairman and chief scientific officer of Celgene Cellular Therapeutics, a division of Celgene Corporation (NASDAQ: CELG), since 2014. From 2002 to 2014, he served in various positions at Celgene Cellular Therapeutics, including chief executive officer and president. Prior to joining Celgene Cellular Therapeutics, Robert Hariri was founder, chairman and chief scientific officer at Anthrogenesis Corporation/LIFEBANK, Inc., a privately held biomedical technology and service corporation involved in the area of human stem cell therapeutics, which was acquired by Celgene Corporation in 2002. Robert Hariri also serves as president of Human Longevity Cellular Therapeutics, Inc., a privately-held genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, which he co-founded in 2013. He has also served as co-founder, vice chairman and chief scientific officer of Neurodynamics, a privately held medical device and technology corporation. Robert Hariri is an adjunct associate professor of pathology at the Mount Sinai School of Medicine and has also held key academic positions at Weill Medical College of Cornell University and the Cornell University Graduate School of Medical Science, including serving as the director of the Center for Trauma Research. Robert Hariri is also a director of Cryoport, Inc. (NASDAQ: CYRX), Bionik Laboratories Corp. (OTCQX: BNKL), Provista Diagnostics and Rocket Racing, Inc. Robert Hariri is a member of the scientific advisory board for the Archon X Prize for Genomics, which is awarded by the X Prize Foundation. Robert Hariri also serves as a trustee of the J. Craig Venter Institute, a trustee of the Liberty Science Center and a commissioner of the New Jersey Commission for Cancer Research. Robert Hariri received the Thomas Alva Edison Award in 2007 and 2011, The Fred J. Epstein Lifetime Achievement Award in 2012 and numerous other honors for his contributions to biomedicine and aviation. He has served as a member of the board of visitors at Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons. Robert Hariri received his undergraduate training at Columbia College and Columbia University School of Engineering and Applied Sciences and was awarded his M.D. and Ph.D. degrees from Cornell University Medical College. Robert Hariri received his surgical training at The New York Hospital-Cornell Medical Center and directed the Aitken Neurosurgery Laboratory and the Center for Trauma Research. We believe Robert Hariri’s training as a scientist, his knowledge and experience with respect to the biomedical and pharmaceutical industries and his extensive research and experience qualifies him to serve on our Board of Directors.
Follow Robert J. Hariri, M.D., Ph.D.:
About Celularity, Human Longevity, Icahn School of Medicine at Mount Sinai, MYOS: Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.
Chad Robins
Co-Founder, President & CEO of Adaptive Biotechnologies
Chad Robins is Adaptive’s President, Chief Executive Officer and Co-founder. He has held executive-level positions in real estate, investing and medical technology, including: Pulte Homes, Connaught Real Estate Finance, and HealthAxis.com. Chad Robins started his career in banking for companies such as Wasserstein Perella and Bank of America. In 2012, Chad Robins was a “40 Under 40” Seattle Leaders honoree. In 2015, he and his brother, Harlan Robins, were honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Chad Robins was also a finalist for the Ernst & Young 2016 Entrepreneur Of The Year® Award in the Pacific Northwest. While in college and looking for a way to combine his adventuresome spirit with a vast learning opportunity, he spent 100 days in the wilderness with the National Outdoor Leadership School (NOLs) where he gained his open and interactive leadership style along with his strong teamwork mentality. A Cornell University honors graduate with a major in entrepreneurship and business, Chad Robins obtained his MBA from The Wharton School at the University of Pennsylvania with a major in finance and concentrations in marketing and operations. In addition to the Adaptive Biotechnologies board, Chad Robins holds board positions for the American Heart Association (Puget Sound) and Pavia Systems. He is also the co-founder and Director of Aortica Corporation, a company that is simplifying endovascular repair (EVAR) for abdominal aortic aneurysms (AAA).
Follow Chad Robins:
About Adaptive Biotechnologies: Adaptive Biotechnologies translates a scale and precision of the adaptive immune system into products to diagnose and treat disease.
Daphne Koller
Founder & CEO of Insitro
Daphne Koller is CEO and Founder of insitro, a company using machine learning and high-throughput biology to transform drug discovery. Daphne was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years. She was the co-founder, co-CEO and President of Coursera for 5 years, and Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She is the author of over 200 refereed publications appearing in venues such as Science, Cell, and Nature Genetics. Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012. She received the MacArthur Foundation Fellowship in 2004 and the ACM Prize in Computing in 2008. She was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017.
Follow Daphne Koller:
About Engageli, Insitro: Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
Eric Ostertag
Chief Executive Officer & Founder of Poseida Therapeutics
Eric Ostertag is the CEO at Poseida Therapeutics.
Follow Eric Ostertag:
About Hera Testing Laboratories, Poseida Therapeutics: Poseida Therapeutics is a biotechnology company that utilizes genome engineering capabilities to develop targeted life-saving therapeutics.
J. Joseph Kim
Co-Founder/President/CEO/Director of Inovio Pharmaceuticals
J. Joseph Kim is the Co-Founder/President/CEO/Director at Inovio Pharmaceuticals.
Follow J. Joseph Kim:
About Inovio Pharmaceuticals, The Aspen Institute: Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Jack Taunton
Founder of Cedilla Therapeutics
Associate Professor at UCSF.
Follow Jack Taunton:
About Cedilla Therapeutics, Global Blood Therapeutics, Kezar Life Sciences, Principia Biopharma, The Howard Hughes Medical Institute, University of California, San Francisco: Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Alan D’Andrea
Co-Founder of Cedilla Therapeutics
Alan D’Andrea brings years of research insights into DNA repair pathways, oncoproteins and ubiquitin to Cedilla. A professor of radiation oncology at Harvard Medical School, Alan also serves as director of the Center for DNA Damage and Repair at Dana-Farber Cancer Institute. Alan’s research centers on the molecular signaling pathways that regulate the cellular response to DNA damage, with a particular focus on the pathogenesis of human chromosome instability and the identification of novel interacting proteins. Alan is a graduate of Harvard Medical School and a member of the National Academy of Medicine.
Follow Alan D’Andrea:
About Cedilla Therapeutics, Dana-Farber Cancer Institute: Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Raghu Kalluri
Scientific Founder of Codiak Biosciences
Raghu Kalluri is Chairman and Professor of the Department of Cancer Biology and the Director of the Metastasis Research Center at The University of Texas MD Anderson Cancer Center, where he also holds the Rebecca and Joseph Brown Endowed Chair. CPRIT funding helped bring Raghu Kalluri to Texas from Harvard Medical School in 2012. Raghu Kalluri received his Ph.D. in Biochemistry and Molecular Biology from the University of Kansas Medical Center and his M.D. degree from Brown University Medical School. He was a postdoctoral fellow and a research associate at the University of Pennsylvania Medical School and performed research in areas of immunology and organ fibrosis. In 1997, he moved to Harvard Medical School as an Assistant Professor of Medicine and as a faculty based in the Department of Medicine at the Beth Israel Deaconess Medical Center. Subsequently, Kalluri was appointed the Chief of the Division of Matrix Biology and promoted to Professor of Medicine at Harvard Medical School. He held appointments in the Department of Biological Chemistry and Molecular Pharmacology at HMS, Harvard MIT Division of Health Sciences and Technology, Harvard Stem Cell Institute and was a research fellow of the HMS Peabody Society. Kalluri has trained more than 70 postdoctoral fellows and 20 graduate students in his career. He is a fellow of American Society of Clinical Investigation and the American Association for the Advancement of Science. In addition, Kalluri serves on science and health advisory panels in the U.S. and European Union and on the editorial boards of several academic journals representing biology and medicine.
Follow Raghu Kalluri:
About Codiak Biosciences: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Stephen Cary
Founder of Omniox
Stephen Cary is the co-founder and CEO of Omniox, and co-inventor of the H-NOX technology. Stephen identified H-NOX as a potential therapeutic platform while working at the University of California, Berkeley. He secured the first financial support for Omniox by winning the inaugural Rogers Family Foundation “Bridging the Gap” Award at QB3. Subsequently, Stephen and his team obtained multiple NIH SBIR awards and a Wellcome Trust Translation Award to build Omniox’ operations and enable development of the H-NOX platform. Prior to launching Omniox, Stephen worked at Genentech in Market Strategy, and before that in Immunology Research. He participated extensively in early stage development projects, concentrating on strategic processes of transitioning therapeutic candidates from late-stage research to early development, and provided market and endpoint inputs into design of clinical trials. Stephen obtained his PhD in Biological Chemistry with Michael Marletta at the University of Michigan, and his Bachelor of Science degree in Molecular Biophysics & Biochemistry at Yale University.
Follow Stephen Cary:
About Omniox: Omniox, a biotechnology company, commercializes technologies used in identifying and treating cancer, cardiovascular disease and trauma.
Jeffrey Port
Co-Founder & Chairman of Angiocrine Bioscience
Jeffrey Port is the Founder of Angiocrine Bioscience, Inc.
Follow Jeffrey Port:
About Angiocrine Bioscience, RF Surgical Systems, TMRW Life Sciences, Weill Cornell Medicine, Weill Cornell Medicine: Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
John Klacking
Co-Founder of Angiocrine Bioscience
John Klacking is the Founder of Angiocrine Bioscience.
Follow John Klacking:
About Angiocrine Bioscience: Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
Shahin Rafii
Scientific Founder of Angiocrine Bioscience
Shahin Rafii is the Founder of Angiocrine Bioscience.
Follow Shahin Rafii:
About Angiocrine Bioscience: Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
James Spudich
Founder of MyoKardia
James Spudich, Ph.D., serves as the Douglass M. and Nola Leishman Professor of Cardiovascular Disease in the Department of Biochemistry at Stanford University. His laboratory studies how enzymes use specific structural elements to carry out their exquisite roles. Specifically, his research has focused on the myosin family of enzymes. Over the last 35 years, Dr. Spudich and scientists in his lab have used an interdisciplinary and multifaceted approach to elucidate the molecular basis of energy transduction by the myosin family of molecular motors. Dr. Spudich also serves as a visiting faculty member at the National Center for Biological Sciences of the Tata Institute of Fundamental Research in Bangalore, India. Dr. Spudich is a co-founder and former director of Cytokinetics and the Stanford University Bio-X program. He currently serves as the chair of the International Affairs Committee for the American Society for Cell Biology, and has previously served as president of the organization. Dr. Spudich has been recognized with numerous honors for his achievements in the field, including the American Heart Association Basic Research Prize and the 2012 Lasker Basic Medical Research Award. He is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences and the American Association for the Advancement of Science. He has authored more than 190 peer-reviewed publications. Dr. Spudich holds a B.S. in chemistry from the University of Illinois at Champaign-Urbana and Ph.D. in biochemistry from Stanford University. He completed his postdoctoral work in genetics and structural biology at Stanford University and the MRC Laboratory of Molecular Biology in Cambridge, England.
Follow James Spudich:
About MyoKardia: MyoKardia is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of rare cardiovascular diseases.
Christine Seidman
Founder of MyoKardia
Christine (Kricket) Seidman, M.D., is a Professor of Genetics and the Thomas W. Smith Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital. She is also an investigator of the Howard Hughes Medical Institute. She joined the staff at Brigham and Women’s Hospital in 1987 and is currently the director of the Cardiovascular Genetics Center. Along with her husband Jonathan Seidman, Ph.D., Dr. Seidman has elucidated multiple genetic causes of human disorders affecting the heart and vasculature. The Seidmans’ discoveries include the identification and demonstration of genetic mutations causing hypertrophic cardiomyopathy and dilated cardiomyopathy, as well as the first genetic cause of congenital heart malformations. In addition to recognition received jointly with her husband, Dr. Seidman’s recent honors include Distinguished Scientist, American Heart Association; Distinguished Alumni Achievement Award, The George Washington University; The 21st Annual Glorney-Raisbeck Award; and the Jay and Jean Schottenstein Prize in Cardiovascular Science. She is a member of the Association of University Cardiologists and an elected member to the National Academy of Sciences. Dr. Seidman holds an undergraduate degree from Harvard College and an M.D. from George Washington University School of Medicine. Dr. Seidman served as an intern and resident in internal medicine at John Hopkins Hospital and received subspecialty training in cardiology at the Massachusetts General Hospital.
Follow Christine Seidman:
About MyoKardia: MyoKardia is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of rare cardiovascular diseases.
Leslie Leinwand
Founder of MyoKardia
Professor at University of Colorado.
Follow Leslie Leinwand:
About MyoKardia, University of Colorado: MyoKardia is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of rare cardiovascular diseases.
Jonathan Seidman
Founder of MyoKardia
Professor at Harvard Medical School.
Follow Jonathan Seidman:
About Harvard Medical School, MyoKardia: MyoKardia is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of rare cardiovascular diseases.
Brent Stockwell
Founder, Scientific Advisor of Kyras Therapeutics
Brent R. Stockwell, Ph.D. is the academic founder of Kyras and is a Professor at Columbia University in the Departments of Biological Sciences and Chemistry; he is also a member of Columbia’s Herbert Irving Comprehensive Cancer Center, Motor Neuron Center, Stem Cell Initiative, Translational Neuroscience Initiative, and Institute for Data Sciences and Engineering. He serves as Director of the Columbia NYSTEM Chemical Probe Synthesis Facility, co-Director of the Columbia High-Throughput Screening Center, and Chair of the Educational Policy and Planning Committee of the Faculty of Arts and Sciences. His research involves the discovery of precision medicines that can be used to understand and treat cancer and neurodegeneration. In recent years, he has pioneered new approaches to target historically undruggable, but medically important, proteins. Dr. Stockwell has received numerous awards, including a Burroughs Wellcome Fund Career Award at the Scientific Interface, a Beckman Young Investigator Award, the BioAccelerate NYC Prize, a Early Career Scientist award from the Howard Hughes Medical Institute, the Lenfest Distinguished Columbia Faculty Award and the Great Teacher of Columbia College Award from the Society of Columbia Graduates. He has trained more than 80 students, technicians and postdoctoral scientists, published >80 scientific articles, two book chapters, been awarded 14 US patents, and received >40 research grants for >$20 million. He co-founded the biotechnology company CombinatoRx Incorporated in 2000, and is the author of The Quest for the Cure: The Science and Stories Behind the Next Generation of Medicines.
Follow Brent Stockwell:
About Kyras Therapeutics: Kyras Therapeutics is a biotech company
Jo Viney
Co-Founder, President and Chief Scientific Officer of Pandion Therapeutics
Follow Jo Viney:
About Pandion Therapeutics: Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
